ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,745.50
-0.07%
S&P ASX All Technology
3,080.00
0.04%
Brent Oil
86.61
0.09%
US Dollar vs AUD
1.50399
0.08%
Bitcoin
62,861.96
0.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lexeo Therapeutics Inc (LXEO)

  7. Lexeo Therapeutics Inc (LXEO) News

LXEO

Lexeo Therapeutics (LXEO)

Lexeo Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LXEO
DateTimeSourceHeadlineSymbolCompany
14/06/202423:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
13/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
23/05/202407:03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
15/05/202406:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
14/05/202407:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
09/05/202421:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LXEOLexeo Therapeutics Inc
09/05/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
09/05/202421:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXEOLexeo Therapeutics Inc
09/05/202421:00GlobeNewswire Inc.Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
07/05/202421:30GlobeNewswire Inc.Lexeo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LXEOLexeo Therapeutics Inc
22/04/202421:30GlobeNewswire Inc.Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
16/04/202421:30GlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
14/03/202407:22GlobeNewswire Inc.Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
12/03/202407:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
12/03/202407:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LXEOLexeo Therapeutics Inc
12/03/202400:29Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LXEOLexeo Therapeutics Inc
11/03/202422:42GlobeNewswire Inc.Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202422:30GlobeNewswire Inc.Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
07/02/202409:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
07/02/202409:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
05/02/202423:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
05/02/202423:00GlobeNewswire Inc.Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsNASDAQ:LXEOLexeo Therapeutics Inc
03/01/202423:00GlobeNewswire Inc.Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
18/12/202323:00GlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)NASDAQ:LXEOLexeo Therapeutics Inc
11/12/202323:00GlobeNewswire Inc.Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LXEO

Your Recent History

ASX
XJO
S&P ASX 200
ASX
ORG
Origin Energy
NYSE
VZ
Verizon Communications
ASX
WES
Wesfarmers
FX
AUDJPY
AUD vs Yen
ASX
BHP
BHP
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
ASX
XFL
S&P ASX 50
ASX
WOW
Woolworths
ASX
NCM
Newcrest Mining
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
AMZN
Amazon.com
ASX
XTO
S&P ASX 100
ASX
CSL
CSL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved